Biohaven (NYSE:BHVN) Downgraded by Wall Street Zen to Sell

Wall Street Zen downgraded shares of Biohaven (NYSE:BHVN) from a hold rating to a sell rating in a research note issued to investors on Saturday,Wall Street Zen reports.

Several other brokerages also recently weighed in on BHVN. Royal Bank Of Canada increased their target price on Biohaven from $19.00 to $22.00 and gave the company a “sector perform” rating in a research note on Friday, October 23rd. HC Wainwright reaffirmed a “neutral” rating and issued a $10.00 target price on shares of Biohaven in a report on Thursday, September 10th. Canaccord Genuity Group lifted their price target on Biohaven from $21.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Morgan Stanley upped their price target on Biohaven from $19.00 to $21.00 and gave the stock an “overweight” rating in a report on Tuesday, November 3rd. Finally, Raymond James Financial reiterated a “strong-buy” rating on shares of Biohaven in a report on Thursday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.80.

Biohaven Stock Up 3.8%

Biohaven stock opened at $14.42 on Friday. The firm has a market cap of $2.18 billion, a price-to-earnings ratio of -3.74 and a beta of 1.36. The company has a debt-to-equity ratio of 21.23, a current ratio of 3.05 and a quick ratio of 3.05. Biohaven has a fifty-two week low of $7.48 and a fifty-two week high of $18.24. The firm has a fifty day moving average price of $13.61 and a two-hundred day moving average price of $12.31.

Biohaven (NYSE:BHVN) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.15). As a group, analysts forecast that Biohaven will post -3.05 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in BHVN. Russell Investments Group Ltd. grew its position in Biohaven by 107.8% during the third quarter. Russell Investments Group Ltd. now owns 150,112 shares of the company’s stock worth $2,004,000 after buying an additional 77,890 shares in the last quarter. Commonwealth Equity Services LLC bought a new position in Biohaven during the third quarter valued at about $135,000. Profund Advisors LLC raised its holdings in Biohaven by 5.6% in the 3rd quarter. Profund Advisors LLC now owns 57,036 shares of the company’s stock valued at $761,000 after acquiring an additional 3,018 shares in the last quarter. Sigma Planning Corp raised its holdings in Biohaven by 43.1% in the 3rd quarter. Sigma Planning Corp now owns 19,944 shares of the company’s stock valued at $266,000 after acquiring an additional 6,008 shares in the last quarter. Finally, Sterling Capital Management LLC raised its holdings in Biohaven by 847.5% in the 3rd quarter. Sterling Capital Management LLC now owns 4,444 shares of the company’s stock valued at $59,000 after acquiring an additional 3,975 shares in the last quarter. Institutional investors and hedge funds own 88.78% of the company’s stock.

Key Biohaven News

Here are the key news stories impacting Biohaven this week:

• Positive Sentiment: Biohaven says a pivotal Phase 3 trial of BHV-1300 for Graves’ disease is underway and presented three research posters at the American Thyroid Association meeting. The program could address a disease with few recent treatment advances, though trial progress is not a guarantee of success. Biohaven Graves’ disease Phase 3 and ATA announcement
• Positive Sentiment: HC Wainwright raised several future EPS estimates, including narrowing its projected losses for 2026–2029 and forecasting positive EPS in 2030. These revisions may bolster expectations for longer-term financial improvement.
• Positive Sentiment: A separate report says a Morgan Stanley analyst expects BHVN shares to rise, adding a favorable analyst signal; the article headline does not provide the rationale or target. Morgan Stanley analyst outlook
• Negative Sentiment: Despite its improved forecasts, HC Wainwright maintained a Neutral rating and a $10 price target, below the recent share price—suggesting that the analyst sees downside relative to current levels.

About Biohaven

Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and neuropsychiatric diseases, as well as certain immunological and rare disorders. The company’s research activities include small-molecule medicines, monoclonal antibodies and other innovative therapeutic approaches.

Biohaven’s pipeline has included investigational treatments for conditions such as migraine, obsessive-compulsive disorder, spinal muscular atrophy, amyotrophic lateral sclerosis, mood disorders and autoimmune diseases.